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Abstract
We discuss a recent Nature Medicine publication by Philip Johnson and co-workers (Vector-
mediated gene transfer engenders long-lived neutralizing activity and protection against SIV
infection in monkeys. Nat. Med. 2009, 15: 901-906) in which an effective HIV-1 vaccine was designed
that is based on gene therapy. The introduced gene produces an antibody-like immunoadhesin in
the blood that neutralizes the virus.
Commentary
The current status of HIV vaccines
The quest for a vaccine against the human immunodefi-
ciency virus type 1 (HIV-1) has recently been given a bad
prognosis [1]. Most attempts at developing an HIV-1 vac-
cine have used substances (immunogens) aimed at stimu-
lating the body's own immune system to produce
antibodies or killer T cells that would either neutralize the
virus during transmission from one to the other host (pro-
tective vaccine) or control the level of virus replication in
an individual who is already infected by HIV-1 (therapeu-
tic vaccine). Such traditional HIV vaccines have not elic-
ited protective immune responses, and it is apparent that
out-of-the-box thinking is needed to generate some truly
innovative ideas that should help us in this HIV-1 vaccine
crisis.
A genetic twist to HIV-1 vaccines
The study by Philip Johnson and his colleagues of the
Children's Hospital in Pennsylvania published in a recent
issue of Nature Medicine presents an unorthodox, yet sur-
prisingly simple approach. These authors used gene trans-
fer technology to produce antibody-like molecules in the
blood that effectively block viral infection [2]. First, they
created artificial antibody-like proteins called immunoad-
hesins that were specifically designed to bind to the sim-
ian immunodeficiency virus (SIV) that infects macaques
to cause an AIDS-like disease. Second, a gene therapy
approach was used to deliver the antiviral immunoad-
hesin gene into the macaques. This immunoadhesin gene
therapy approach bypasses the immune system alto-
gether, and promising results were reported in the pre-
clinical macaque model. The insights gained from how to
achieve protection against SIV infection by a gene therapy
approach could possibly be translated to the control of
HIV-1 infection in humans.
Antiviral immunoadhesins
The antibody genes chosen in the study are immunoad-
hesins, artificial chimeric antibody-like molecules that
were pre-selected to bind the Envelope protein (Env
gp120) on the SIV virions. The immunoadhesins are
based on two previously characterized gp120-specific Fab
clones from SIV-infected macaques. These Fabs show
potent  in vitro neutralizing capacity against the
SIVmac316 isolate, and also against other SIV strains. The
immunoadhesins were designed by coupling the variable
heavy (VH) and variable light (VL) chains from the Fabs via
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a linker to an IgG2 Fc fragment of the rhesus macaque
(constructs 4L6 and 5L7). In a separate construct N4, the
IgG2 domain was fused to the rhesus macaque CD4 mol-
ecule (domain 1 and 2), the primary receptor for SIV entry
into cells. The purpose of both the Fab and the CD4 mol-
ecules is to block the viral Envelope protein and thus
abrogate the capability of the virus to bind and infect tar-
get cells. Based on the binding affinity, it could be
expected that CD4 would be less efficient in virus neutral-
ization than the Fabs. In addition, the CD4 molecules
may cause unwanted side effects through interaction with
other molecules of the immune system, e.g. the T cell
receptor complex.
AAV gene therapy vector
A harmless adeno-associated virus (AAV) vector was used
to deliver the antiviral immunoadhesin or CD4 gene. The
AAV vector has some clear advantages over the traditional
use of adenoviruses or other vector systems in gene ther-
apy. First, AAV has a relatively low immunogenicity and
only triggers the synthesis of neutralizing antibodies, but
no cytotoxic T cell activity. Second, AAV vectors can pro-
vide a durable therapeutic effect because of the high trans-
duction efficiency and the accumulation of episomal
concatamers. A disadvantage of AAV vectors is the limited
cloning capacity, which complicates the usage of large
genes. The traditional AAV vector was used for insertion of
the CD4 gene. As pointed out by the authors, by cloning
the expression cassettes between the AAV inverted termi-
nal repeats (ITR), two genomes can anneal to double the
capacity of the vector. This novel vector arrangement was
used for the immunoadhesin genes. The authors con-
firmed that the designed immunoadhesin-IgG2 genes
were functionally expressed. Initial tests were performed
in mice [3], and based on promising results, the authors
moved to the macaque model.
Macaque immunization
Three groups of 3 rhesus macaques were immunized by
intramuscular AAV injection. The animals received either
the 4L6 or 5L7 vector encoding an anti-SIV immunoad-
hesin or the N4 vector that encodes the rhesus macaque
CD4 molecule. All macaques showed a detectable level of
transgene protein expression in the sera. The immunoad-
hesin concentration in the blood was similarly high for
the 4L6 and 5L7 vectors, and persisted for over a year. A
somewhat reduced protein level was measured for the N4
vector, which could be due to differences in the AAV vec-
tor used. We note that both the AAV vector and the
SIVmac316 challenge virus stock were prepared in the
human 293-HEK cell line, which may cause cross-species
reactions that were not addressed in the study design that
used unvaccinated control animals.
The SIV challenge experiment
The 9 immunized macaques and 6 control non-immu-
nized macaques were challenged one month after immu-
nization by intravenous injection of the live, AIDS-
causing SIVmac316 strain. This challenge was repeated to
ensure virus transmission, and indeed all control
macaques became infected. Four of these control animals
had to be sacrificed due to AIDS-related complications,
and only a single animal was able to suppress spontane-
ously viral replication. In contrast, 6 of the 9 immunized
macaques remained uninfected after challenge. Further-
more, none of the 9 immunized animals suffered any
AIDS-related complications for up to 85 weeks. The pro-
tection induced by the immunoadhesin expressing 4L6
vector seemed most effective (3 of 3 animals tested), fol-
lowed by the CD4-IgG2 expressing vector N4. The single
5L7 animal that was protected from infection showed a
pattern of immunoadhesin abundance and neutralization
activity similar to the 4L6 monkeys.
All control macaques developed SIV-specific gp120 and
Gag antibodies due to the successful infection. The 3
immunized macaques that appeared not to be protected
against SIV challenge also developed antibodies against
gp120, which could in fact be distinguished from the anti-
gp120 immunadhesin expressed from the AAV vector. The
6 protected macaques exhibited different neutralization
patterns. The 4L6 and 5L7 groups showed a higher level of
neutralizing titers than the N4 group. The macaques that
failed to be protected by AAV-immunization, 2 animals in
the 5L7 group and 1 in the N4 group, showed a strong
immunoadhesin-specific antibody response in compari-
son with the protected animals that did not develop any
immune reaction against the immunoadhesins. The posi-
tive role of the IgG2 Fc domain in the effector functions of
the immunoadhesin warrants further studies.
Towards an HIV-1 vaccine
Based on the important proof of concept in the SIV-
macaque model, the Johnson team is gearing up for clini-
cal trials with potential "superantibodies" from people
who spontaneously resist HIV-1 infection. At the same
time, the authors cautioned that many hurdles remain
before the technique used in this animal study might be
translated into an HIV-1 vaccine for humans. The
approach is still in the early stages of animal testing, and
there is much to do in order to prove that this approach
could yield a successful and safe vaccine that protects
against HIV-1 infection. For instance, the monkeys were
challenged by direct SIV injection in the blood, exactly the
location where the antiviral immunoadhesins reside.
Additional tests will be needed to show that the vaccine
also protects against sexually acquired virus, as the virus
may not encounter the antiviral immunoadhesins in thisRetrovirology 2009, 6:93 http://www.retrovirology.com/content/6/1/93
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natural transmission route across the mucosa during the
first days of virus replication.
Any test of vector-mediated delivery of protective anti-
body genes will require extensive tests with a range of anti-
bodies and subsequent optimization tests before human
safety studies can take place. For instance, the best protec-
tion was observed in those animals that did not mount an
immune response against the immunoadhesin vaccine.
This finding would argue for the development of
improved "humanized" versions of the vaccine so that the
human body does not produce vaccine-inactivating anti-
bodies, which then would also allow repeated treatments
as booster vaccinations. The final choice of antibody will
depend on its ability to protect against the different HIV-
1 subtypes. A combination of antibodies could be devel-
oped to widen the breadth of the antiviral response. Alter-
natively, it may be better to develop several subtype-
specific gene vaccines that can be used in matching geo-
graphic regions, e.g. subtype A in West Africa and subtype
C in East Africa. Repeated and massive viral challenges
should be done in long-term follow-up experiments to
test the longevity of protection and to study the potential
for the evolution of vaccine-escape virus variants that
could theoretically start to spread in an unrestricted man-
ner in the "gene vaccine protected" population.
Such an unorthodox gene-based vaccine will likely be
tested first in small groups of volunteers with a high risk
of infection, e.g. discordant couples where one partner is
HIV-positive and the other could be vaccinated. As the
proposed vaccine will not likely be given to the general
population, vector production issues seem less of an
urgent issue. These issues would include the stability of
the AAV vectors and the ability to manufacture large-scale
quantities of these vectors in a cost-effective manner.
Finally, this gene vaccination technology may also have
potential use in the prevention of other infectious diseases
that resist orthodox vaccination strategies.
Alternative vaccine approaches
One could argue that the only hope of controlling the HIV
pandemic is to develop a protective vaccine. The urgency
to do so has not really been tempered. HIV-1 has killed 25
million people since the early 1980s and currently infects
33 million individuals. Even if the gene therapy technique
leads to an effective HIV vaccine, such a vaccine may be
years away from practical application. Thus, it seems wise
to develop more unconventional vaccination strategies in
order to spread our chances on winning the battle against
HIV-1. This includes the use of replication-competent
viral delivery systems [4] and possibly even the use of safe
versions of a live-attenuated HIV-1 vaccine [5]. In addi-
tion, one should speed up approaches to remodel the viral
Env protein such that it becomes an effective immunogen
that elicits neutralizing antibodies [6]. It cannot be pre-
dicted which method will turn out to be the best in terms
of vaccine efficacy and breadth of protection. A renewed
focus on live-attenuated virus variants seems warranted to
define the correlates of protection, a pivotal issue that can-
not be learned from the premade immunoadhesin strat-
egy.
Alternative gene therapy approaches
Future gene therapy has been proposed for individuals
who are already infected by HIV-1. Several gene therapy
trials are ongoing with antiviral molecules such as
ribozymes [7] or inhibitors based on the mechanism of
RNA interference (RNAi) [8]. The RNAi approaches have
yielded especially impressive results when targeting the
viral RNA genome [9], but one could also think of target-
ing an important cellular co-factor. The CCR5 receptor is
an obvious and attractive target. HIV-1 infected people
who carry a defective CCR5 gene, CCR5-Δ32, show
delayed disease progression, and people homozygous for
CCR5-Δ32 are healthy and largely protected from HIV-1
infection [10]. Targeting of CCR5, resulting in perhaps
only a partial knock-down, is expected to provide a thera-
peutic benefit for HIV-infected patients. This potential
was recently highlighted in a proof of principle study in
non-human primates [11]. Primates received blood stem
cells treated with an SIV lentiviral vector expressing a
shRNA against CCR5. CCR5 expression was knocked
down and T cells from these primates were found to be
less susceptible to SIV infection as compared to the appro-
priate control cells. The primates exhibited normal hemat-
opoietic reconstitution, an important indication that the
treatment is safe.
The potential of such an anti-CCR5 gene therapy is further
supported by the functional cure of an HIV-infected
patient, who had leukemia in addition to AIDS, and
received a special bone marrow transplant [12]. The
patient's medical condition warranted the high risk blood
stem cell transplant, although 10% to 30% of people who
receive bone marrow transplants die. Even though the
odds are extremely small, a donor was identified who was
both a good tissue match and a carrier of the CCR5-inac-
tivating mutation. Prior to the transplant, a standard regi-
men of drugs and radiation was administered to kill the
patient's bone marrow cells and many cells of the
immune system. Antiretroviral treatment was stopped
when the donor cells were transfused because of concerns
about their survival ability. While the plan was to resume
the antiretroviral regimen once HIV-1 re-emerged in the
patient's blood, standard tests have not detected HIV-1 in
his blood for more than 600 days. As stated above, this
treatment is unthinkable for the millions of people living
with HIV/AIDS. Nevertheless, the results form a "virtualPublish with BioMed Central    and   every 
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proof of principle" for the safety and efficacy of CCR5-tar-
geting gene therapy approaches in humans.
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